Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Zosano Pharma Corp (ZSAN) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/19/2022 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
06/03/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/18/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
05/18/2022 8-K Quarterly results
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/13/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
04/29/2022 10-K/A Annual Report for the period ended December 31, 2021 [amend]
04/11/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation of Zosano Pharma Corporation",
"Zosano Pharma Announces Reverse Stock Split Effective Today ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022"
04/01/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/17/2022 10-K Annual Report for the period ended December 31, 2021
03/17/2022 8-K Quarterly results
Docs: "Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results"
02/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/18/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/11/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/11/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/09/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, between Zosano Pharma Corporation and Maxim Group LLC",
"Form of Series F Warrant",
"Opinion of Latham & Watkins LLP",
"Form of Warrant Agency Agreement",
"Form of Voting Agreement"
02/09/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/08/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/31/2022 8-K Investor presentation
Docs: "DESIGNED TO ADDRESS UNMET NEEDS IN MIGRAINE 7"
01/24/2022 8-K Other Events  Interactive Data
01/05/2022 8-K Other Events  Interactive Data
12/13/2021 8-K Quarterly results
11/30/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/17/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System"
11/10/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/10/2021 8-K Quarterly results
Docs: "Zosano Pharma Reports Third Quarter 2021 Financial Results"
10/29/2021 8-K Other Events  Interactive Data
10/06/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
10/04/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amendment No. 1, effective as of September 29, 2021, to Master Services Agreement by and between the Company and Eversana Life Science Services, LLC",
"Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results"
08/10/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/10/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy